Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
4Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Cognition Therapeutics, Inc. (CGTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
4Distinct source URLs
9High confidence
0.807Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Cognition Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
JEFFERIES-LLC
JEFFERIES-LLC
92%
The Company may sell, from time to time, at its option, shares of the Company’s common stock, through or to Jefferies, as sales agent or principal (the “ATM Offering”).
THIRD-PARTY-CONTRACT-MANUFACTURER
THIRD-PARTY-CONTRACT-MANUFACTURER
92%
Currently, we rely on and have agreements with a single third-party contract manufacturer to supply the zervimesine drug substance and with a single third-party contract manufacturer to manufacture c…
B-RILEY-SECURITIES-INC
B-RILEY-SECURITIES-INC
90%
On December 16, 2025, the Company delivered written notice to B. Riley Securities, Inc. to terminate the Previous Sales Agreement, effective December 18, 2025.
LINCOLN-PARK-CAPITAL-FUND-LLC
LINCOLN-PARK-CAPITAL-FUND-LLC
85%
On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Park Capital Fund, LLC for an equity line financing.
JEFFERIES
JEFFERIES
80%
which registered the offering, issuance and sale of up to $ 300.0 million of various equity and debt securities and up to $ 75,000 of common stock pursuant to an at-the-market equity offering program…
tured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from th…
Reciprocal relationship from ORANY graph: Reciprocal relationship from CGTX graph: tured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restri…
the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the pa…
Reciprocal relationship from ORANY graph: Reciprocal relationship from CGTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from CGTX graph: Reciprocal relationship from ORAN…
ANNUAL-REPORT-EMERGING-GROWTH-COMPANY
ANNUAL-REPORT-EMERGING-GROWTH-COMPANY
62%
he number and development requirements of other product candidates that we may pursue; ● the costs, timing and outcome of regulatory review of our product candidates; ● the costs and timing of future…
LINCOLN-PARK-CAPITAL-FUND-LLC
LINCOLN-PARK-CAPITAL-FUND-LLC
62%
incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture …
Cognition Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CGTX-DEBT-8616
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
CGTX-DEBT-8615
Warrants outstanding: 34000
90%
xbrl warrant detail from xbrl 2021-12-31.
CGTX-DEBT
Debt stack $638,000
90%
Market cache reports total debt of $638,000.
Cognition Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Cognition Therapeutics, Inc..
Cognition Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
CGTX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 75 tracked holders.
Cognition Therapeutics, Inc. Extended Supply Chain Network
